RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 190 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 1.13 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $60,603 | +7.5% | 7,922 | +4.9% | 0.00% | 0.0% |
Q2 2023 | $56,391 | +12.0% | 7,549 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $50,352 | -22.0% | 7,549 | -9.9% | 0.00% | 0.0% |
Q4 2022 | $64,571 | -27.5% | 8,375 | 0.0% | 0.00% | -25.0% |
Q3 2022 | $89,110 | +30.7% | 8,375 | 0.0% | 0.00% | +33.3% |
Q2 2022 | $68,173 | +23.8% | 8,375 | +8.9% | 0.00% | +50.0% |
Q1 2022 | $55,053 | -89.5% | 7,689 | -74.8% | 0.00% | -71.4% |
Q4 2021 | $522,842 | +179.4% | 30,522 | +275.2% | 0.01% | +133.3% |
Q3 2021 | $187,163 | -23.1% | 8,134 | +22.0% | 0.00% | 0.0% |
Q2 2021 | $243,346 | – | 6,667 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Obvious Management Services, L.L.C. | 3,985,087 | $42,401,000 | 100.00% |
Two Sigma Ventures, LP | 903,400 | $9,612,000 | 100.00% |
DCVC Opportunity Fund II GP, LLC | 3,951,141 | $42,040,000 | 54.37% |
Data Collective IV GP, LLC | 5,941,120 | $63,214,000 | 49.97% |
MIC Capital Management UK LLP | 8,451,758 | $89,927,000 | 16.21% |
MV Management XI, L.L.C. | 1,971,908 | $20,981,000 | 15.20% |
ArchPoint Investors | 1,116,126 | $11,876,000 | 4.85% |
HARVARD MANAGEMENT CO INC | 1,509,254 | $16,058,000 | 2.00% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,251,971 | $23,961,000 | 1.00% |
Duquesne Family Office | 1,385,950 | $14,747,000 | 0.84% |